GlassScriptPhysician profile
Michael S Lava
NPI 1861718272
$3,306.49
in general payments reported to CMS, 2019-2025
25 companies · $274 in 2025
The $274 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,007 · 2020: $459 · 2021: $160 · 2022: $448 · 2023: $669 · 2024: $290 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $736.26 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $589.02 | 2019-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $459.89 | 2019-2024 | Ofev |
| Grifols USA, LLC | $218.71 | 2019-2023 | Prolastin-C Liquid |
| La Jolla Pharmaceutical Company | $217.00 | 2020-2023 | Giapreza |
| Insmed, INC. | $147.14 | 2019 | |
| Genentech USA, INC. | $133.90 | 2019-2023 | Polivy, Columvi |
| Janssen Scientific Affairs, LLC | $126.11 | 2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $115.59 | 2019-2025 | Dupixent |
| Verona Pharma, INC. | $77.43 | 2025 | Ohtuvayre |
| Genzyme Corporation | $71.97 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $62.46 | 2019 | |
| Amgen INC. | $44.52 | 2022-2025 | Tezspire |
| Pulmonx Corporation | $37.28 | 2023-2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Philips North America LLC | $37.24 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $36.60 | 2019-2020 | |
| Abiomed | $34.80 | 2022 | |
| Shire North American Group INC | $34.72 | 2019 | |
| Vapotherm INC | $29.36 | 2021 | |
| Mallinckrodt Hospital Products INC. | $20.88 | 2022 | |
| Chiesi USA, INC. | $17.40 | 2020 | |
| Baxter Healthcare | $16.73 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Teva Pharmaceuticals USA, INC. | $14.84 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.81 | 2021 | |
| Mylan Specialty L.P. | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.